發(fā)布時間：2018-11-03 17:37

【摘要】：在經歷了兩次世界大戰(zhàn)之后,中印兩國均在20世紀中葉取得了各自的獨立,建國初期,印度政府基本上沿用了英國殖民統(tǒng)治時期的專利法,中國則完全照搬了前蘇聯(lián)的專利制度。直到20世紀70年代,兩國才重新根據(jù)本國的國情建立起了符合各自國家發(fā)展利益的專利制度。由于中印兩國同為人口大國,并且兩國當時的公共衛(wèi)生基礎設施及其薄弱,為滿足公共衛(wèi)生的需要,兩國都在制定專利法的時候將涉及醫(yī)藥制品排除在了可授予專利保護的范圍之外,這一點也是符合當時兩國國情的。制藥產業(yè)不僅對經濟的發(fā)展和科技的進步具有重要的推動作用,其對公共健康衛(wèi)生的影響作用是其他產業(yè)所無法企及的。中印兩國的制藥工業(yè)在制造能力上都己進入世界大國行列,尤其是大宗抗生素的生產,兩國基本能左右國際市場行情。但是與西方發(fā)達國家先進制藥行業(yè)相比較,中印兩國的差異也是極為明顯的,其中一個最為突出方面就是缺乏充足的擁有完全自主知識產權的藥品。這無疑使得兩國在應對國內可能出現(xiàn)嚴重的公共衛(wèi)生危機時捉襟見肘。在進入21世紀之后,特別是兩國先后成為了世界貿易組織成員國之后,印度在對待本國專利法與國際接軌的問題上,采取的手段明顯要更加靈活一些。這一點從印度在加入世界貿易組織之后對于本國專利法的修改便可察覺,印度并未一味的強調高標準的專利保護,而是緩慢的對其專利法進行不斷的修正,以符合其國內社會經濟的發(fā)展需求,正是這種務實的態(tài)度,使得印度制藥行業(yè)為代表的國內經濟充分得到了法律政策層面上的庇護,并且在經過了一定時期的積累后從容的升級,終究在世界經濟全球化的今天發(fā)展成為可以與西方同行抗衡的重要力量,為印度在應對今后可能出現(xiàn)的公共衛(wèi)生危機時,提供了一定的產業(yè)支持。本文通過對印度在其專利制度發(fā)展上的策略和手段的研究,試圖對我國今后的藥品專利制度的發(fā)展提供一些借鑒,特別是在當下追求將知識產權保護標準提高到西方發(fā)達國家水平成為主流的時代,我國如何做到在既不與國際相關條約和協(xié)議沖突的條件下,又能充分利用專利制度作為調整國家產業(yè)政策升級的法律工具來進行綜合考量。
[Abstract]:After two world wars, both China and India gained their independence in the middle of the 20th century. In the early days of the founding of India, the Indian government basically followed the patent laws of the British colonial rule. China, for its part, copied the patent system of the former Soviet Union. It was not until the 1970s that the two countries re-established the patent system according to their national conditions. Because China and India are both populous countries, and their public health infrastructure was weak at the time, to meet the needs of public health, Both countries are making patent laws to exclude pharmaceutical products from the scope of patent protection, which is also in line with the situation of the two countries at that time. Pharmaceutical industry not only plays an important role in promoting the development of economy and the progress of science and technology, but also affects public health and health. The pharmaceutical industry of both China and India has entered the ranks of the world's largest countries in terms of manufacturing capability, especially in the production of major antibiotics, and both countries can basically control the international market. But compared with the advanced pharmaceutical industry in the western developed countries, the difference between China and India is also very obvious, one of the most prominent aspects is the lack of adequate medicines with full independent intellectual property rights. This undoubtedly puts the two countries in a tight position to cope with a potentially serious public health crisis at home. After entering the 21st century, especially after the two countries have become members of the World Trade Organization, India has to take more flexible measures in dealing with its patent law in line with the international law. This can be seen from India's amendment to its patent law after its accession to the World Trade Organization. Instead of emphasizing high standards of patent protection, India has been slowly revising its patent law. In keeping with its domestic socio-economic development needs, it is this pragmatic attitude that has given the domestic economy, represented by the Indian pharmaceutical industry, full protection at the legal and policy levels, And after a certain period of accumulation, after a relaxed upgrade, after all, in the face of the globalization of the world economy, it has developed into an important force that can compete with its Western counterparts, so that India can cope with a possible public health crisis in the future. Provide certain industry support. This paper attempts to provide some references for the future development of drug patent system in China through the study of India's strategy and means in the development of its patent system. Especially in the current era when the standard of intellectual property protection has become the mainstream of the western developed countries, how to do it without conflict with the relevant international treaties and agreements, It can also make full use of patent system as a legal tool to adjust the upgrading of national industrial policy for comprehensive consideration.
【學位授予單位】：南昌大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：D923.42

【參考文獻】

相關期刊論文 前10條

1 張海興;;TRIPs體制下公共健康專利強制許可制度的發(fā)展趨勢[J];牡丹江大學學報;2016年12期

2 劉彬;;仿制藥品立法規(guī)制的發(fā)展新態(tài)勢——以TPP醫(yī)藥專利條款為視角[J];荊楚理工學院學報;2016年03期

3 楊燕琳;;印度藥品專利強制許可制度的啟示[J];哈爾濱學院學報;2016年02期

4 俞鋮航;田侃;喻小勇;;印度藥品專利強制許可制度分析及對中國的啟迪[J];中國新藥雜志;2016年03期

5 郝敏;;藥品專利強制許可制度在發(fā)展中國家的應用——從“抗癌藥代購第一人”陸勇事件談起[J];知識產權;2015年08期

6 張清奎;李紅團;;關于藥品專利強制許可制度的探討和思考[J];藥學進展;2015年08期

7 馮潔菡;;專利本地實施要求的合法性之爭——國際法與國內法實踐評析[J];暨南學報(哲學社會科學版);2014年09期

8 孔祥俊;;積極打造我國知識產權司法保護的“升級版”——經濟全球化、新科技革命和創(chuàng)新驅動發(fā)展戰(zhàn)略下的新思考[J];知識產權;2014年02期

9 張?zhí)?邵蓉;;公共健康危機視野下藥品專利強制許可制度的探討[J];上海醫(yī)藥;2012年17期

10 張茅;;深化醫(yī)藥衛(wèi)生體制改革 促進衛(wèi)生事業(yè)科學發(fā)展[J];求是;2012年15期

相關重要報紙文章 前1條

1 黃天香 ;任麗梅 ;一軒;;遞交惠民新答卷 造福尋常百姓家[N];中國改革報;2012年

相關博士學位論文 前1條

1 張艷梅;藥品專利法律問題研究[D];吉林大學;2008年

相關碩士學位論文 前8條

1 李瑩瑩;環(huán)境技術專利強制許可制度研究[D];華中師范大學;2015年

2 徐山茶;論我國藥品專利強制許可制度的實施[D];西南大學;2014年

3 王乃嘉;我國藥品專利強制許可制度的實現(xiàn)路徑及其完善研究[D];蘭州大學;2014年

4 舒佳英;我國藥品專利強制許可制度研究[D];華東政法大學;2013年

5 周玲;中印專利強制許可問題比較研究[D];華中師范大學;2013年

6 王金明;全球專利藥到期潮背景下的制藥企業(yè)投資分析[D];上海交通大學;2013年

7 武振康;中印藥品專利強制許可制度比較研究[D];華中科技大學;2012年

8 張冬;新專利法下藥品專利強制許可制度研究[D];復旦大學;2009年

，

本文編號：2308481